Bas J. Blaauboer

Bas J. Blaauboer

Auto-generated profile, based on publicly available information

Bas J. Blaauboer

Division of Toxicology, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2002 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
GEG Eisenbrand
G Eisenbrand
BPB Pool-Zobel
B Pool-Zobel
VBV Baker
V Baker
MBM Balls
M Balls
BBB.J Blaauboer
B.J Blaauboer
JKJ Kleiner
J Kleiner

1 June 2015 in Toxicology
Verified
Journal Article
Closed access
FGFloris A. Groothuis
Floris A. Groothuis
MHMinne Heringa
Minne Heringa
BNBeate Nicol
Beate Nicol
JHJoop L.M. Hermens
Joop L.M. Hermens
BBBas. J. Blaauboer
Bas. J. Blaauboer
NKNynke I. Kramer
Nynke I. Kramer

1 June 2013 in Toxicology in Vitro
Verified
Journal Article
Closed access
AMAlberTinka J. Murk
AlberTinka J. Murk
EREddy Rijntjes
Eddy Rijntjes
BBBas J. Blaauboer
Bas J. Blaauboer
RCRebecca Clewell
Rebecca Clewell
KCKevin M. Crofton
Kevin M. Crofton
AGArno Christian Gutleb
Arno Christian Gutleb

1 February 2013 in Journal of Proteomics
Verified
Journal Article
Open access
AWAnja Wilmes
Anja Wilmes
ALAlice Limonciel
Alice Limonciel
LALydia Aschauer
Lydia Aschauer
KMKonrad Moenks
Konrad Moenks
CBChris Bielow
Chris Bielow
PJPaul Jennings
Paul Jennings
High content omic techniques in combination with stable human in vitro cell culture systems have the potential to improve on current pre-clinical safety regimes by providing detailed mechanistic information of altered cellular processes. Here we investigated the added benefit of integrating transcriptomics, proteomics and metabolomics together with pharmacokinetics for drug testing regimes. Cultured human renal epithelial cells (RPTEC/TERT1) were exposed to the nephrotoxin Cyclosporine A (CsA) at therapeutic and supratherapeutic concentrations for 14days. CsA was quantified in supernatants and cellular lysates by LC-MS/MS for kinetic modeling. There was a rapid cellular uptake and accumulation of CsA, with a non-linear relationship between intracellular and applied concentrations. CsA at 15μM induced mitochondrial disturbances and activation of the Nrf2-oxidative-damage and the unfolded protein-response pathways. All three omic streams provided complementary information, especially pertaining to Nrf2 and ATF4 activation. No stress induction was detected with 5μM CsA; however, both concentrations resulted in a maximal secretion of cyclophilin B. The study demonstrates for the first time that CsA-induced stress is not directly linked to its primary pharmacology. In addition we demonstrate the power of integrated omics for the elucidation of signaling cascades brought about by compound induced cell stress.

1 October 1987 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
ARAlphons A. J. J. L. Rutten
Alphons A. J. J. L. Rutten
HFHein E. Falke
Hein E. Falke
JCJan F. Catsburg
Jan F. Catsburg
RTRandy Topp
Randy Topp
BBBas J. Blaauboer
Bas J. Blaauboer
FLF. X. Rolaf van Leeuwen
F. X. Rolaf van Leeuwen

17 June 2010 in Journal of Toxicology and Environmental Health, Part B
Verified
Journal Article
Closed access
BBBas J. Blaauboer
Bas J. Blaauboer
The introduction of in vitro methodologies in the toxicological risk assessment process requires a number of prerequisites regarding both the toxicodynamics and the biokinetics of the compounds under study. In vitro systems will need to be relevant for measuring those structural and physiological changes that are good indicators for adverse effects. Furthermore, the dose metric found to have an effect in the in vitro system should be relevant. One element in defining the appropriate dose metric is related to the kinetic behavior of the compound in the in vitro system: binding to proteins, binding to plastic, evaporation, and the interaction between the culture medium and the cells. Ways to measure and model “in vitro biokinetics” are described. Second, the appropriate dose metric in vitro, e.g., the effective concentration, will need to be extrapolated to relevant in vivo exposure scenarios. The application of physiologically based biokinetic modelling is essential in such extrapolations. The parameters needed to build these models often can be estimated based on nonanimal data, namely chemical properties (QSARs) and in vitro experiments.